One data source is an argument. Two independent data sources agreeing is evidence.
That principle sits at the heart of defensible validation – and it is exactly what a recent project demonstrated when Enzyme Indicator data and Computational Fluid Dynamics simulation were used together to characterise H₂O₂ distribution inside an isolator.
The setup
The team needed to identify and justify worst-case locations across the isolator chamber. This is a familiar challenge: which positions should be monitored during qualification, and how do you defend that selection to an auditor?
Traditionally, worst-case locations are selected based on engineering judgement, prior experience, or empirical BI mapping. Our poll data from a recent webinar showed that 39% of teams use a combination of methods – but only 3% currently use CFD, and 18% have no formal worst-case rationale at all.
This project took a different approach: characterise the chamber using two independent technologies and compare the results.
CFD: predicting distribution
A CFD simulation modelled H₂O₂ vapour flow and concentration throughout the isolator, accounting for chamber geometry, airflow paths, and the injection system. The model predicted:
- Areas of strong, direct vapour exposure (typically near injection points and in the main airflow path).
- Areas of reduced concentration (corners, recesses, and positions shielded by equipment or structural features).
- Transition zones where exposure was adequate but less uniform.
This gave the team a physics-based map of expected distribution – before a single physical cycle was run.
EIs: measuring what actually happened
During physical cycle runs, Enzyme Indicators were placed at positions across the chamber, including the locations CFD had flagged as potentially weaker. The EI data – quantitative RLU readouts available in approximately 60 seconds – showed:
- Positions near injection points received the strongest exposure, consistent with the CFD prediction.
- Positions in recessed or shielded areas showed measurably reduced (but still adequate) inactivation, again matching the simulation.
- The relative ranking of positions by exposure level aligned between the two methods.
Two fundamentally different approaches – one computational, one empirical – arrived at the same characterisation of the chamber.
Why convergence matters
For validation teams, this kind of agreement between independent methods has significant practical value:
Stronger worst-case justification. Selecting worst-case locations based on “engineering judgement” is defensible to a point. Selecting them based on CFD prediction confirmed by empirical EI data is substantially stronger. The rationale does not rest on a single method or a single person’s experience.
More efficient qualification design. When CFD and EI data agree on which positions are well-exposed and which are marginal, teams can focus BI placement where it matters most – at the positions that genuinely represent worst-case conditions. This supports a more targeted, risk-based approach rather than blanket coverage.
Better documentation for regulatory review. Regulatory submissions increasingly benefit from layered evidence. A package that includes simulation data, quantitative exposure measurements, and BI kill confirmation tells a more complete story than BI results alone.
Troubleshooting support. If a position shows unexpected results during qualification, having both CFD and EI baselines makes it far easier to diagnose whether the issue is a distribution problem, a placement problem, or an indicator problem.
The practical implication
CFD and EI monitoring are not dependent on each other – either adds value independently. But when used together, they create a validation narrative that is difficult to challenge: the physics says this should happen, the empirical measurement confirms it does, and the BI data verifies lethality.
For teams building or reviewing their worst-case rationale, this convergence approach offers a clear path to documentation that is both scientifically robust and practically efficient.
Next in the series: Where regulators stand on Enzyme Indicators today – and a practical framework for getting started.
